- $532.91m
- $546.97m
- $36.97m
Brief: Clearpoint Neuro Set To Join Russell 3000 Index
Clearpoint Neuro Inc reports results for the quarter ended in March - Earnings Summary
Clearpoint Neuro Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Clearpoint Neuro Inc - Upon John N. Spencer, Jr's Retirement, Size Of Board Shall Decrease From Seven To Six Members
Brief: Clearpoint Neuro's Director John N. Spencer, Jr. Retires
Brief: Clearpoint Neuro Reports Q4 2020 Results
U.S. STOCKS ON THE MOVE-Casa Systems, Baidu, Applied Materials, Evolus
U.S. STOCKS ON THE MOVE-JinkoSolar, Riot, Bloomin' Brands, Six Flags
ClearPoint Neuro drops after pricing $43 mln equity offering
Brief: Clearpoint Neuro Announces Pricing Of Public Offering Of 1.85 Mln Shares Of Common Stock
Brief: ClearPoint Neuro Launches Proposed Public Offering Of Common Stock
Brief: Clearpoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement With Blackrock Microsystems
Brief: ClearPoint Neuro Inc Says Size Of Board Was Decreased From Eight To Seven Members
Brief: ClearPoint Neuro Inc Appointments John Fletcher As Chairman Of The Board Of Directors
Brief: Clearpoint Neuro, Inc. Announces Expansion Of Pre-Clinical And Translational Development Team To Support Gene And Stem Cell Therapy Partners
Brief: Clearpoint Neuro Inc Files For Mixed Shelf Of Upto $120 Mln
Brief: ClearPoint Neuro Announces First Procedure Utilizing Clearpoint 2.0 Software In Europe
Clearpoint Neuro: Rises on higher prelim Q4 revenue forecast
Brief: Clearpoint Neuro Reports Record Revenue In Preliminary Q4 2020 Results